Active Ingredient History
Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent. In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4, potential activators of CYP3A5 and inhibitors of the P-gp transporter. Most common adverse reactions are bleeding 12% and dyspnea 14%. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (approved 2011)
Myocardial Infarction (approved 2011)
Acute Coronary Syndrome (Phase 4)
Acute Lung Injury (Phase 1)
Adenosine (Phase 2)
Anemia, Sickle Cell (Phase 3)
Aneurysm (Phase 4)
Angina Pectoris (Phase 4)
Angina, Stable (Phase 4)
Angina, Unstable (Phase 4)
Angioplasty (Phase 4)
Angioplasty, Balloon, Coronary (Phase 4)
Ankle Injuries (Phase 4)
Antithrombins (Phase 4)
Aortic Aneurysm, Abdominal (Phase 2)
Aortic Stenosis, Subvalvular (Phase 4)
Aortic Valve Stenosis (Phase 4)
Arterial Occlusive Diseases (Phase 3)
Arthritis, Rheumatoid (Phase 4)
Aspirin (Early Phase 1)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Biological Availability (Phase 1)
Blood (Phase 1)
Blood Platelet Disorders (Phase 4)
Blood Platelets (Phase 4)
Cardiovascular Diseases (Phase 4)
Carotid Stenosis (Phase 2)
Cerebral Infarction (Phase 3)
Chest Pain (Phase 4)
Chronic Limb-Threatening Ischemia (Phase 1/Phase 2)
Community-Acquired Infections (Phase 2)
Constriction, Pathologic (Phase 4)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Coronary Stenosis (Phase 4)
Critical Illness (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug-Eluting Stents (Phase 4)
Drug Interactions (Phase 4)
Drugs, Investigational (Phase 4)
Embolism (Phase 4)
Endomyocardial Fibrosis (Phase 4)
Endothelial Cells (Phase 4)
Endothelium (Phase 4)
Fibrinolysis (Phase 4)
Foramen Ovale, Patent (Phase 3)
Fractional Flow Reserve, Myocardial (Phase 4)
Gout (Phase 1)
Headache (Phase 4)
Healthcare-Associated Pneumonia (Phase 1)
Healthy Volunteers (Phase 4)
Heart (Phase 4)
Heart Arrest (Phase 4)
Heart Diseases (Phase 4)
Hemorrhage (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Hypothermia, Induced (Phase 4)
Infarction (Phase 4)
Inflammation (Phase 4)
Intermittent Claudication (Phase 4)
Intracranial Aneurysm (Phase 3)
Intracranial Arteriosclerosis (Phase 2/Phase 3)
Ischemia (Phase 4)
Ischemic Attack, Transient (Phase 3)
Ischemic Stroke (Phase 3)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Liver Transplantation (Phase 3)
Lung Diseases (Phase 4)
Metabolism (Phase 3)
Microvascular Angina (Phase 4)
Migraine Disorders (Phase 4)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Myocardial Stunning (Phase 4)
Myocardium (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 4)
No-Reflow Phenomenon (Phase 4)
Pediatrics (Phase 3)
Percutaneous Coronary Intervention (Phase 4)
Peripheral Arterial Disease (Phase 4)
Peripheral Vascular Diseases (Phase 3)
Pharmacokinetics (Phase 3)
Pharmacology (Phase 1)
Plaque, Atherosclerotic (Phase 4)
Platelet Aggregation (Phase 4)
Platelet Aggregation Inhibitors (Phase 4)
Pneumonia (Phase 1)
Post-Cardiac Arrest Syndrome (Phase 4)
Prostheses and Implants (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Renal Insufficiency, Chronic (Phase 4)
RNA (Early Phase 1)
Shock, Cardiogenic (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stents (Phase 4)
Stroke (Phase 4)
Therapeutic Equivalency (Phase 1)
Thrombosis (Phase 4)
Ticagrelor (Phase 4)
Transcatheter Aortic Valve Replacement (Phase 4)
Vascular Access Devices (Phase 1/Phase 2)
Vascular Diseases (Phase 4)
Vascular Grafting (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
